2-5 July – Barcelona (Spain)
The ESMO Gastrointestinal Cancers Congress (ESMO GI) 2025, held in Barcelona, brought together leading clinicians, researchers, and patient advocates to discuss the latest advances in gastrointestinal oncology and the future of personalised cancer care.
During the meeting, discussions around ctDNA-guided strategies in colon cancer highlighted the growing importance of liquid biopsy in helping guide treatment decisions after surgery. This approach lies at the heart of the SAGITTARIUS clinical trial.
In this context, Dr. Clara Montagut, Chair of the SAGITTARIUS study, presented results from the PEGASUS clinical trial, a previous study that explored how circulating tumour DNA (ctDNA) can help identify patients who may benefit from tailored treatment strategies. These findings contribute to the scientific foundation on which SAGITTARIUS builds, further investigating how ctDNA and tumour genomics can support more personalised treatment for patients with high-risk stage II and operable stage III colon cancer.
The discussions at ESMO GI underscored the relevance and potential impact of the research questions it addresses. Events like ESMO GI play an important role in fostering collaboration among researchers and clinicians working toward more precise and patient-centred approaches to colon cancer care.
For more information
For more information about the SAGITTARIUS project or to take part in the trial, please contact: clinical.trials@ifom.eu.
To be updated about the SAGITTARIUS project:
- Media contact: info@sagittarius-horizon.eu
- SAGITTARIUS social media profiles: LinkedIn, Facebook, X, Instagram, YouTube
- Subscribe to the SAGITTARIUS newsletter.